PriceTargets.com logo

Axcella Health - AXLA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.40 As of 12/29/2023 01:00 AM ET
+0 (0.00%)
Get New Axcella Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXLA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXLA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Axcella Health in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.40.

This chart shows the closing price for AXLA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Axcella Health. This rating has held steady since January 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/22/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/23/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/16/2023HC WainwrightReiterated RatingNeutral
12/16/2022Leerink PartnersReiterated RatingOutperform ➝ Market Perform$150.00 ➝ $50.00
12/15/2022HC WainwrightDowngradeBuy ➝ Neutral
11/2/2022WedbushReiterated RatingOutperform$150.00
11/2/2022Chardan CapitalLower TargetBuy$175.00 ➝ $125.00
11/2/2022HC WainwrightLower Target$250.00 ➝ $200.00
10/3/2022HC WainwrightBoost TargetBuy$200.00 ➝ $250.00
8/3/2022HC WainwrightLower TargetBuy$350.00 ➝ $200.00
8/3/2022Leerink PartnersLower TargetOutperform$225.00 ➝ $150.00
5/27/2022WedbushLower Target$175.00
5/9/2022Chardan CapitalLower TargetBuy$300.00 ➝ $175.00
3/31/2022Leerink PartnersLower TargetOutperform$250.00 ➝ $225.00
12/16/2021Roth CapitalReiterated RatingBuy
11/16/2021Chardan CapitalBoost TargetBuy$250.00 ➝ $300.00
10/12/2021Noble FinancialInitiated CoverageOutperform$150.00
9/22/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$225.00 ➝ $125.00
7/30/2021Leerink PartnersInitiated CoverageBuy$250.00
7/30/2021Chardan CapitalReiterated RatingBuy$250.00
7/30/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
7/6/2021HC WainwrightInitiated CoverageBuy$350.00
6/3/2021Chardan CapitalLower TargetBuy$400.00 ➝ $250.00
3/20/2021WedbushReiterated RatingBuy$475.00 ➝ $275.00
11/26/2020Chardan CapitalReiterated RatingBuy$400.00
11/18/2020Roth CapitalInitiated CoverageBuy$700.00
10/27/2020Chardan CapitalInitiated CoverageBuy$400.00
10/26/2020Leerink PartnersReiterated RatingOutperform$250.00
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutral
9/25/2020B. RileyInitiated CoverageBuy$350.00
9/24/2020B. RileyReiterated RatingBuy
8/27/2020WedbushReiterated RatingBuy$475.00
8/14/2020WedbushReiterated RatingBuy$475.00
8/12/2020The Goldman Sachs GroupReiterated RatingBuy$225.00
8/6/2020Leerink PartnersLower TargetOutperform$500.00 ➝ $250.00
7/30/2020Piper SandlerInitiated CoverageOverweight$625.00
7/9/2020BTIG ResearchLower TargetBuy$700.00 ➝ $400.00
5/27/2020WedbushInitiated CoverageOutperform$700.00 ➝ $700.00
(Data available from 5/23/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/23/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/22/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Axcella Health logo
Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $0.40
Low: $0.36
High: $0.51

50 Day Range

MA: $0.84
Low: $0.40
High: $4.58

52 Week Range

Now: $0.40
Low: $0.34
High: $41.25

Volume

6,782 shs

Average Volume

267,009 shs

Market Capitalization

$1.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Axcella Health?

The following Wall Street analysts have issued stock ratings on Axcella Health in the last year:
View the latest analyst ratings for AXLA.

What is the current price target for Axcella Health?

0 Wall Street analysts have set twelve-month price targets for Axcella Health in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Axcella Health in the next year.
View the latest price targets for AXLA.

What is the current consensus analyst rating for Axcella Health?

Axcella Health currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AXLA.

What other companies compete with Axcella Health?

Other companies that are similar to Axcella Health include Titan Pharmaceuticals, Aptose Biosciences, Organovo, Genetic Technologies and Palisade Bio. Learn More about companies similar to Axcella Health.

How do I contact Axcella Health's investor relations team?

Axcella Health's physical mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company's listed phone number is (857) 320-2200 and its investor relations email address is [email protected]. The official website for Axcella Health is www.axcellahealth.com. Learn More about contacing Axcella Health investor relations.